Erlotinib Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Erlotinib Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
930
Registered trials
1114
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Erlotinib Hydrochloride can convert its Small molecule drug profile and EGFR L858R x EGFR-Ex19del biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Erlotinib Hydrochloride (query alias: erlotinib) |
|---|---|
| Modality / target | Small molecule drug; EGFR L858R x EGFR-Ex19del; EGFR exon 19 deletion inhibitors, EGFR exon 21 L858R mutation inhibitors |
| Highest global status | Approved |
| Originator | OSI Pharmaceuticals, Inc., Pfizer Inc. |
| Active developers | Eli Lilly & Co., Shanghai Roche Pharmaceuticals Ltd., Genentech, Inc. |
The MCP disease footprint includes EGFR positive non-small cell lung cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600122769 | Phase 4 | Not yet recruiting | 18 | Maximum Tolerated Dose (MTD) |
| NCT06997068 | Phase 2 | Recruiting | 25 | Rates of provider referral and patient enrollment (Feasibility) |
| NCT07418177 | Phase 1/2 | Not yet recruiting | 9 | Number of subjects with adverse events |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Adjuvant erlotinib versus observation after complete resection of EGFR-mutant NSCLC: Final overall survival results of Alliance A081105.
Phase 3; n=390; evaluation: Negative. Reported fields: OS(5-year) = 77.9 % ; OS(5-year) = 78.6 %
Ultra-low-dose immunotherapy plus oral metronomic chemotherapy versus paclitaxel-carboplatin in platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma: A randomized phase III trial.
Phase 3; n=422; evaluation: Positive. Reported fields: mOS = 6.2 month ; mOS = 10.3 month
MC240701: Decentralized pilot study of triple oral metronomic chemotherapy in recurrent/metastatic oral cavity cancer.
Phase 2; n=25; evaluation: Positive. Reported fields: Feasibility of decentralized clinical trials = After initial screening and evaluation, patients are remotely consented and will receive study drugs by mail. All subsequent clinical and laboratory monitoring and response assessments (every 3 cycles) will be remotely performed or have an option for local testing.
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Erlotinib Hydrochloride addresses EGFR positive non-small cell lung cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-05-15 | CHEPLAPHARM expands oncology portfolio with Tarceva® from Roche | Approved | Financial terms not disclosed |
| 2021-03-29 | 百洋医药第三方商业化平台又添新伙伴，签入罗氏制药两大经典肿瘤药 | Approved | Financial terms not disclosed |
| 2001-01-08 | OSI Pharmaceuticals, Genentech and Roche Team up to Deveolp and Commercialize OSI-774, OSI's Leading Cancer Drug to Develop and Commercialize OSI-774, OSI's Lead Cancer Drug | Phase 2 | US$187.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
